首页> 外文学位 >Indole-3-Carbinol Mediated Anti-Proliferative Regulation of Breast Cancer Stem Cells and Malignant Melanoma-Initiating Cells
【24h】

Indole-3-Carbinol Mediated Anti-Proliferative Regulation of Breast Cancer Stem Cells and Malignant Melanoma-Initiating Cells

机译:吲哚-3-甲醇介导的乳腺癌干细胞和恶性黑色素瘤起始细胞的抗增殖调控。

获取原文
获取原文并翻译 | 示例

摘要

The cancer stem cell theory ascertains a subpopulation of tumorigenic cells that selectively possess the ability for tumor initiation and self-renewal capacity to differentiate into nonmalignant cancer cells, known as bulk tumor cells. Cancer stem cells were first identified in hematopoietic cancers but subsequently have been implicated in ovarian, melanoma, liver, sarcoma, head and neck, pancreatic, glioblastoma, and breast cancers since. As a result, malignant tumors can be composed of genetically and morphologically heterogeneous cell populations with varying degrees of differentiation, self-renewal ability, and metastatic capacity. Experimental pursuits have sought to isolate and analyze the cancer stem cell population in primary tumors and molecularly strategize to identify phenotypic targets. A lack of standardized cancer stem cell in vivo and in vitro models have slowed down the development of proper therapies as well as the elucidation of scientific mechanisms that dictate cancer stem cells. One method of detection has been the utilization of various stem cell markers to categorize molecular phenotypes. In breast cancer stem cells, biomarkers such as the nucleolar GTPase nucleostemin; the detoxifying enzyme, ALDH-1; and cell surface marker, CD44 aid in identification and isolation of cancer stem cells for research studies. Furthermore, exclusion of the Hoescht Dye assays for the cell's ability to efflux current therapeutic molecules extra-cellullarly, evading apoptosis and cell cycle arrest. Furthermore, melanoma cancer stem cells, also known as malignant melanoma-initiating cells (MMICs), contain subpopulations expressing CD133, CD20, and ABCG5 have defined features of unlimited self-renewal and proliferative capacities for melanoma cancers. While cancer incidence overall has decreased, melanoma continues to rise, with patients with metastatic and malignant melanoma continue to relapse from current therapeutic strategies. This thesis details the characterization of human breast cancer and melanoma cell lines of varying tumorigenic potential and their subsequent response to the phytochemical, indole-3-carbinol, and its synthetic derivative, 1-benzyl-I3C. I3C selectively targets breast cancer stem cells through different molecular mechanisms such as protein-protein interactions of the stem cell marker nucleostemin and its binding partner, murine double mutant 2 (MDM2) in the nucleolus, thereby freeing p53 to activate apoptosis. Furthermore, I3C sensitizes cells with a wild type p53, wild type PTEN phenotype or even more tumorigenic melanoma cells that possess the rare BRAF V600D mutation and PTEN deletion. Given I3C's and its more potent derivative, 1-benzyl-I3C's, anti-proliferative modulation of the p53 pathway in breast cancer cells and the PTEN/ Wnt pathways in malignant melanoma cell lines, preclinical results can implicate I3C as a novel chemopreventative molecule that selectively targets cancer stem cells.
机译:癌症干细胞理论确定了致瘤细胞的亚群,这些亚群选择性地具有引发肿瘤的能力和自我更新的能力,以分化为非恶性癌细胞,称为批量肿瘤细胞。癌症干细胞首先在造血系统癌症中被鉴定,但此后与卵巢癌,黑素瘤,肝癌,肉瘤,头颈癌,胰腺癌,胶质母细胞瘤和乳腺癌相关。结果,恶性肿瘤可由具有不同程度的分化,自我更新能力和转移能力的遗传和形态异质细胞群体组成。已经进行了实验性探索以分离和分析原发性肿瘤中的癌症干细胞群体,并进行分子策略以鉴定表型靶标。体内和体外模型缺乏标准化的癌症干细胞,已经减缓了正确疗法的发展以及对决定癌症干细胞的科学机制的阐明。一种检测方法是利用各种干细胞标记物对分子表型进行分类。在乳腺癌干细胞中,生物标记物如核仁GTPase核蛋白;排毒酶ALDH-1;和细胞表面标记物CD44有助于鉴定和分离癌症干细胞,以进行研究。此外,排除了Hoescht Dye分析的细胞在细胞外释放当前治疗分子的能力,从而避免了细胞凋亡和细胞周期停滞。此外,黑素瘤癌症干细胞,也称为恶性黑素瘤起始细胞(MMIC),包含表达CD133,CD20和ABCG5的亚群,这些亚群具有针对黑素瘤癌症无限的自我更新和增殖能力的特征。尽管总体上癌症的发病率下降了,但黑色素瘤继续上升,转移性和恶性黑色素瘤患者继续从目前的治疗策略中复发。本论文详细介绍了具有不同致癌潜力的人乳腺癌和黑色素瘤细胞系的表征,以及它们对植物化学吲哚-3-甲醇及其合成衍生物1-苄基I3C的反应。 I3C通过不同的分子机制选择性地靶向乳腺癌干细胞,例如干细胞标志物核蛋白与它的结合伴侣,核仁中的鼠类双突变体2(MDM2)的蛋白质-蛋白质相互作用,从而释放p53激活细胞凋亡。此外,I3C使具有罕见BRAF V600D突变和PTEN缺失的野生型p53,野生型PTEN表型甚至是更多致瘤性黑色素瘤细胞敏感。鉴于I3C及其更有效的衍生物1-苄基I3C,乳腺癌细胞中p53途径的抗增殖调节以及恶性黑色素瘤细胞系中的PTEN / Wnt途径,临床前结果可能暗示I3C作为一种新型的化学预防分子靶向癌症干细胞。

著录项

  • 作者

    Park, Anna Hyo.;

  • 作者单位

    University of California, Berkeley.;

  • 授予单位 University of California, Berkeley.;
  • 学科 Molecular biology.;Oncology.;Cellular biology.;Endocrinology.
  • 学位 Ph.D.
  • 年度 2016
  • 页码 125 p.
  • 总页数 125
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号